Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).
Shannon L PuhallaVéronique DiérasBanu K ArunBella KaufmanHans P M W WildiersHyo S HanJean-Pierre AyoubVered StearnsYuan YuanTeresa HelstenBridget Riley-GillisErin MurphyMadan G KunduMeijing WuDavid MaagChristine K RatajczakCyril Y RamathalMichael L FriedlanderPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Crossover veliparib monotherapy demonstrated limited antitumor activity in patients who experienced disease progression on placebo plus carboplatin/paclitaxel. PFI appeared to affect veliparib activity. BRCA reversion mutations may promote cross-resistance and limit veliparib activity following progression on platinum.